{"id":11410,"date":"2022-01-05T14:38:26","date_gmt":"2022-01-05T13:38:26","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?page_id=11410"},"modified":"2025-01-17T14:18:20","modified_gmt":"2025-01-17T13:18:20","slug":"curasight","status":"publish","type":"page","link":"https:\/\/kapitalpartner.dk\/en\/curasight\/","title":{"rendered":"Curasight"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"11410\" class=\"elementor elementor-11410 elementor-11326\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-0d14333 elementor-section-full_width elementor-section-stretched elementor-section-height-default elementor-section-height-default\" data-id=\"0d14333\" data-element_type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;,&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-no\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-d74a924\" data-id=\"d74a924\" data-element_type=\"column\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-97e4689 elementor-widget elementor-widget-image\" data-id=\"97e4689\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1200\" height=\"292\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/10\/Corporate-Finance-e1667391450167.jpg\" class=\"attachment-full size-full wp-image-25834\" alt=\"\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/10\/Corporate-Finance-e1667391450167.jpg 1200w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/10\/Corporate-Finance-e1667391450167-300x73.jpg 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/10\/Corporate-Finance-e1667391450167-768x187.jpg 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-358d6677 elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"358d6677\" data-element_type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-6ca9be3f\" data-id=\"6ca9be3f\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-10fbc09a elementor-widget elementor-widget-text-editor\" data-id=\"10fbc09a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><a href=\"https:\/\/kapitalpartner.dk\/en\/\">Front page<\/a> &gt; <a href=\"https:\/\/kapitalpartner.dk\/en\/investeringscases\/\">Investment cases<\/a> &gt; Curasight<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-4780224a\" data-id=\"4780224a\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5d004802 elementor-widget elementor-widget-spacer\" data-id=\"5d004802\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-27a18916 elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"27a18916\" data-element_type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-5d8041a3\" data-id=\"5d8041a3\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a2305a6 elementor-widget elementor-widget-video\" data-id=\"a2305a6\" data-element_type=\"widget\" data-settings=\"{&quot;autoplay&quot;:&quot;yes&quot;,&quot;play_on_mobile&quot;:&quot;yes&quot;,&quot;loop&quot;:&quot;yes&quot;,&quot;start&quot;:0,&quot;video_type&quot;:&quot;vimeo&quot;}\" data-widget_type=\"video.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-wrapper elementor-open-inline\">\n\t\t\t<iframe class=\"elementor-video-iframe\" allowfullscreen allow=\"autoplay\" title=\"vimeo Video Player\" src=\"https:\/\/player.vimeo.com\/video\/454096615?autoplay=1&amp;playsinline=1&amp;color&amp;autopause=0&amp;loop=1&amp;muted=0&amp;title=1&amp;portrait=1&amp;byline=1#t=\"><\/iframe>\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-30fe4c05\" data-id=\"30fe4c05\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-449ce5ba elementor-hidden-mobile elementor-widget elementor-widget-image\" data-id=\"449ce5ba\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.curasight.com\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"640\" height=\"428\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg\" class=\"attachment-large size-large wp-image-14484\" alt=\"\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg 850w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1-300x201.jpg 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1-768x514.jpg 768w\" sizes=\"(max-width: 640px) 100vw, 640px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59e72adc elementor-widget elementor-widget-heading\" data-id=\"59e72adc\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">About Curasight<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3379b5a6 elementor-widget elementor-widget-text-editor\" data-id=\"3379b5a6\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers.<\/p><p>The company has developed a radiopharmaceutical platform that can be used both for diagnostics and for the treatment of cancer: <strong>uTRACE<\/strong> &#8211; which is used for cancer diagnostics has been used in more than 400 patients in a number of completed and ongoing investigator-initiated phase II clinical trials; and <strong>uTREAT <\/strong>&#8211; which have been successfully used in the treatment of cancer in translational studies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-2ef9ff9c elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"2ef9ff9c\" data-element_type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4432beb9\" data-id=\"4432beb9\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-54dd3923 elementor-tabs-view-horizontal elementor-widget elementor-widget-tabs\" data-id=\"54dd3923\" data-element_type=\"widget\" data-widget_type=\"tabs.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-tabs\">\n\t\t\t<div class=\"elementor-tabs-wrapper\" role=\"tablist\" >\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1421\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1421\" aria-expanded=\"false\">Why invest in Curasight<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1422\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1422\" aria-expanded=\"false\">Investment case<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1423\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1423\" aria-expanded=\"false\">Facts<\/div>\n\t\t\t\t\t\t\t\t\t<div id=\"elementor-tab-title-1424\" class=\"elementor-tab-title elementor-tab-desktop-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1424\" aria-expanded=\"false\">News<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<div class=\"elementor-tabs-content-wrapper\" role=\"tablist\" aria-orientation=\"vertical\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"true\" data-tab=\"1\" role=\"tab\" tabindex=\"0\" aria-controls=\"elementor-tab-content-1421\" aria-expanded=\"false\">Why invest in Curasight<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1421\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"1\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1421\" tabindex=\"0\" hidden=\"false\"><p><strong>What you see is what you treat!<\/strong><\/p><p>Curasight is a successful Danish theranostic Phase 2 biotech company focused on diagnosing and treating cancer through Targeted Radionuclide Therapy &#8211; currently in brain cancer, prostate cancer, head and neck cancer and neuroendocrine cancer. With Curasight&#8217;s technology (uTRACE and uTREAT), cancer can be diagnosed and treated at the cellular level without harming healthy cells, so that what you can detect of cancer is what you treat with radiation: What you see is what you treat.<\/p><p>The main points of Curasight&#8217;s investment case are therefore a conviction that Cursasight&#8217;s targeted radiotherapy and diagnostics will initially achieve positive progress in the development\/studies and thus that the company will be interesting for partnerships with e.g. Big Pharma and achieve the company&#8217;s objectives. The company has already landed a large deal for uTRACE in prostate cancer in collaboration with Curium, where Curasight will receive up to MUSD 70 in commercial and development milestones and double-digit royalties on sales.<\/p><p><strong>Curasight&#8217;s objectives are:<\/strong><\/p><ul><li>For uTrace to become an alternative to biopsy in prostate cancer and the method used to monitor patients<\/li><li>For uTrace + uTreat to gain a significant market share in brain cancer<\/li><li>Achieve a broad pipeline of cancer indications that will make the company even more attractive for partnerships with Big Pharma<\/li><\/ul><p><strong>Next capital raise:<\/strong><\/p><p>The exercise period for warrants of series TO3 runs from 4 June 2025 up to and including 18 June 2025. The exercise price for warrants of series TO3 will be based on the volume weighted average price (VWAP) of the company&#8217;s shares 20 before the exercise period with a discount of 30 percent, but within the range DKK 15.55-19.40. Upon maximum exercise of warrants of series TO3, Curasight will receive MDKK 35.7 with a dilution of 7 per cent.<\/p><p><strong>Price triggers:<\/strong><\/p><ul><li><p>Q1 2025: CTA submitted for treatment of uTREAT in high-grade glioma<\/p><\/li><li><p>Q2 2025: First patient dosed with uTREAT in high-grade glioma<\/p><\/li><li><p>H2 2025: Topline results from Phase II study of uTRACE in prostate cancer in collaboration with Curium<\/p><\/li><li><p>H2 2025: Preliminary efficacy data from Phase I\/II study of uTREAT (indication to be announced)<\/p><\/li><li><p>2025 or 2026: New milestone payments through the collaboration agreement with Curium<\/p><\/li><li><p>2025 or 2026: Opportunity for new partnerships<\/p><\/li><li><p>2026: First patient enrolled in Phase I\/IIa study of uTREAT in 5 indications (brain cancer, neuroendocrine tumors, non-small cell lung cancer, pancreatic cancer and head and neck cancer)<\/p><\/li><\/ul><p><strong>Curasight&#8217;s pipeline<\/strong><\/p><p>Curasight has divided its portfolio into therapeutic programmes for uTREAT, diagnostics for uTRACE and partner programmes with external companies. Curasight has completed preclinical trials for uTREAT and is currently in the planning phase for Phase I\/IIa. For uTRACE, the company has conducted phase I trials in a wide range of indications, as well as phase II trials in selected indications. Finally, the partner programme is in Phase II for uTRACE in prostate cancer in collaboration with Curium. Curasight is exploring the possibility of entering into more agreements with partners so that there will eventually be more partner programmes. Please note that the investigator initiated studies with uTRACE are paid for by Rigshospitalet (National University Hospital of Denmark).<\/p><p><img decoding=\"async\" class=\"alignnone wp-image-41635\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1.webp\" alt=\"\" width=\"1000\" height=\"359\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1-300x108.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1-768x276.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-41632\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2.webp\" alt=\"\" width=\"1000\" height=\"411\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2-300x123.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2-768x315.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-41629\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3.webp\" alt=\"\" width=\"1000\" height=\"193\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3-300x58.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3-768x148.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"2\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1422\" aria-expanded=\"false\">Investment case<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1422\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"2\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1422\" tabindex=\"0\" hidden=\"hidden\"><h4><strong>What you see is what you treat!<\/strong><\/h4><p><br \/>Curasight is a Phase II Targeted Radionuclide Therapy clinical stage company focused on the diagnosis and treatment (theranostic) of cancer.<\/p><p>Both diagnosis and treatment are based on the uPAR receptor, which most solid cancer cells have, but which healthy cells do not. Curasight has developed a uPAR-binding compound that both identifies the cancer cells (uTRACE) and can irradiate the cancer cells (uTREAT).<\/p><p><strong>uTRACE<\/strong> is injected into the patient&#8217;s blood vessels and binds to the cancer cells, and only to the cancer cells, as they are the only ones that have the uPAR receptor. uTRACE thus binds to the cancer cells regardless of whether it is the primary tumor or metastases. uTRACE emits radiation that can be detected by an image scanner (PET scanner). This makes it possible to see where the cancer cells are and how widespread they are.<\/p><p>The advantages of this method are numerous and significant compared to, for example, diagnosis by taking a biopsy, as it allows for continuous monitoring of cancer patients and patients with brain cancer. In addition, it allows better assessment of the best treatment options, including whether surgery is needed. It also avoids having to operate on patients who did not need surgery, which for prostate cancer is up to 70% of those operated on.<\/p><p><strong>uTREAT<\/strong> basically works in the same way as uTRACE, by injecting the uPAR-binding substance into the patient&#8217;s veins, where it binds to the cancer cells. Unlike uTRACE, the uPAR binding agent has a radionuclide attached to it that can irradiate the cancer cell. As the irradiation has a radius of only 1 mm, only the cancer cells are damaged and not the surrounding healthy tissue.<\/p><p>The advantages of uTREAT over conventional radiotherapy are significant. In conventional radiotherapy, healthy tissue\/cells are also affected, as the radiation is delivered from the outside. Therefore, conventional radiotherapy has many and varied side effects, depending on which and how much healthy tissue is damaged. With uTREAT, only the cancer cells are irradiated, thereby minimizing side effects, which is a significant advantage in brain cancer, for example.<\/p><p>The starting point is therefore that if you can visualize the cancer on a scan image &#8211; then it is very likely that you can also treat the cancer with targeted radionuclide radiotherapy, as the same biomarker, uPAR, and the same substance is used to bind to the receptor in uTRACE and uTREAT &#8211; in other words &#8220;What you see &#8211; is what you treat&#8221;. The studies with uTRACE, which have shown uptake in tumors, thus show that uTREAT will also bind to the tumor and exert its anti-cancer effect through local radiotherapy.<\/p><h4><strong>Pipeline and development<\/strong><\/h4><p>Curasight has continuously expanded its pipeline to cover a number of different indications: brain cancer, prostate cancer, head and neck cancer, non-small cell lung cancer (NSCLC), pancreatic cancer and neuroendocrine cancer. The uTRACE diganostic platform is the most advanced and the easiest and least expensive platform to develop. Curasight has completed 5 phase 2 clinical studies and has plans for phase 3 studies in the future.<\/p><p>uTREAT has previously shown efficacy in preclinical studies in prostate and colon cancer, is in preclinical testing in glioblastoma (aggressive brain cancer). The first step in the testing of new targeted radionuclides is the study of biodistribution, where both binding to the implanted human glioblastoma tumors as well as distribution to organs is tested. The binding to the tumor must be sufficiently high to allow a therapeutic response and the biodistribution to organs must be such that serious side effects are unlikely.<\/p><p>uTREAT has now been tested in a human xenograft glioblastoma tumor model and has passed both criteria, paving the way for further efficacy testing.<\/p><p>Phase II data from an investigator-initiated study with Curasight&#8217;s uTRACE technology, which showed significant potential to become a valuable future tool in therapy, planning and follow-up in patients with head and neck cancer. The results showed that patients with a high uptake of uTRACE have a significantly worse prognosis regarding recurrence-free survival, strengthening the company&#8217;s thesis of uTRACE&#8217;s potential as a tool to measure cancer aggressiveness. Researchers from Rigshospitalet also performed a multivariate analysis with a number of commonly used prognostic markers and concluded that only uTRACE remained significant in terms of recurrence-free survival. This means that uTRACE was not only highly prognostic, but also the strongest prognostic marker among those included in the analysis.<\/p><h4><strong>Business Case<\/strong><\/h4><p>Curasight&#8217;s business model is partly to develop uTRACE and uTREAT in the various indications and partly to expand the number of indications in order to increase the possibilities of entering into partnerships with Big Pharma or obtaining financing for development. Essential elements in this are that the market potential for Curasight&#8217;s platforms is large and that a launch can be achieved as soon as possible.<\/p><p><strong>Brain cancer (Glioblastoma)<\/strong><\/p><p>Approximately 65,000 patients in Europe and the US are diagnosed with brain tumours each year, of which 30,000 are diagnosed with glioma, where treatment prospects are poor. Glioblastoma is a rare disease, which is why there is a possibility of obtaining Orphan Drug Designation and thus a faster path to launch. Approximately 10% of patients are children. The prognosis for people with glioblastoma is very poor, as approximately 50% of patients die within 14 months, and after five years from diagnosis, only 5% are still alive.<\/p><p><strong>Non-small cell lung cancer (NSCLC)<\/strong><\/p><p>NSCLC is the most common type of lung cancer, with 700,000 diagnosed annually in the US and EU. The 5-year survival rate is only 28%, which is why there is a great medical need for more effective therapies. The global market for NSCLC drugs is estimated at USD 15.1bn in 2023 with an annual growth rate of 9.4% to USD 28.3bn in 2030.<\/p><p><strong>Prostate cancer (uTRACE)<\/strong><\/p><p>Up to 70% of patients undergo unnecessary surgery for prostate cancer. As there can be significant side effects of surgery, including impotence, uTRACE could become the primary alternative to biopsies.<\/p><p><b><strong>Head and neck cancer<\/strong><\/b><\/p><p>Head and neck cancer is the 6th most common cancer with 890,000 new cases and 450,000 deaths annually. The incidence is expected to increase in the coming years. The main finding from the phase II study with uTRACE was that patients with high uptake on uPAR-PET compared to those with low uptake had an 8.5 times worse prognosis in terms of recurrence-free survival. And when compared to commonly used prognostic markers (FDG-PET, TNM stage and p16 status) in a multivariate analysis, only uPAR-PET remained significant. The study concluded that uPAR-PET could potentially be valuable for treatment planning and follow-up in patients with head and neck cancer. In addition, the presence of uPAR in head and neck cancer patients, and especially in those with the most aggressive disease, also provided the basis for pursuing uPAR-targeted radionuclide therapy (uTREAT) in this cancer type.<\/p><p><b><strong>Neuroendocrine tumours<\/strong><\/b><\/p><p>Every year, 35,000 new cases of neuroendocrine tumours are diagnosed, which can occur anywhere, but primarily in the lungs and gastrointestinal tract. As the cancer is not particularly fatal, there are more than 400,000 patients with the disease in the US and Europe.<\/p><p><b><strong>Pancreatic cancer<\/strong><\/b><\/p><p>Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide uncontrollably, forming a tumour. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It produces enzymes that aid digestion and hormones that control blood sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer by 2024.<\/p><h4><strong>Overview of the pipeline<\/strong><\/h4><p><img decoding=\"async\" class=\"alignnone wp-image-41635\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1.webp\" alt=\"\" width=\"1000\" height=\"359\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1-300x108.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/1-768x276.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-41632\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2.webp\" alt=\"\" width=\"1000\" height=\"411\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2-300x123.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/2-768x315.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-41629\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3.webp\" alt=\"\" width=\"1000\" height=\"193\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3.webp 1366w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3-300x58.webp 300w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/04\/3-768x148.webp 768w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><\/p><\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"3\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1423\" aria-expanded=\"false\">Facts<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1423\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"3\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1423\" tabindex=\"0\" hidden=\"hidden\">\t\t<div data-elementor-type=\"section\" data-elementor-id=\"11381\" class=\"elementor elementor-11381\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-321bf0e1 elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"321bf0e1\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-29ce39b9\" data-id=\"29ce39b9\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-152c6cc elementor-widget elementor-widget-heading\" data-id=\"152c6cc\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Spotlight  <\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d10900e elementor-widget elementor-widget-image\" data-id=\"d10900e\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/spotlightstockmarket.com\/en\/companies\/irabout?InstrumentId=XSAT000076RH\">\n\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/elementor\/thumbs\/Curasight-Facts-pikflg75e1eh8nqov9wiysios9ueic994mb98yveak.jpg\" title=\"Curasight Facts\" alt=\"Curasight Facts\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-5054fe63\" data-id=\"5054fe63\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-808721e elementor-widget elementor-widget-heading\" data-id=\"808721e\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\"> Nordnet \n\n<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-599a0fe elementor-widget elementor-widget-image\" data-id=\"599a0fe\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.nordnet.dk\/markedet\/aktiekurser\/17339490-curasight\" target=\"_blank\">\n\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/elementor\/thumbs\/Curasight-Nordnet-piwr9qq1oe9l573fwdwp98muqgg5a75f44klm4lf6k.jpg\" title=\"Curasight Nordnet\" alt=\"Curasight Nordnet\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-3643b516\" data-id=\"3643b516\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-25 elementor-top-column elementor-element elementor-element-45a186d1\" data-id=\"45a186d1\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-tab-title elementor-tab-mobile-title\" aria-selected=\"false\" data-tab=\"4\" role=\"tab\" tabindex=\"-1\" aria-controls=\"elementor-tab-content-1424\" aria-expanded=\"false\">News<\/div>\n\t\t\t\t\t<div id=\"elementor-tab-content-1424\" class=\"elementor-tab-content elementor-clearfix\" data-tab=\"4\" role=\"tabpanel\" aria-labelledby=\"elementor-tab-title-1424\" tabindex=\"0\" hidden=\"hidden\">\t\t<div data-elementor-type=\"section\" data-elementor-id=\"13832\" class=\"elementor elementor-13832\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ffb4831 elementor-section-full_width elementor-section-height-default elementor-section-height-default\" data-id=\"ffb4831\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b3f7cba\" data-id=\"b3f7cba\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t<br \/>\n<b>Warning<\/b>:  Undefined array key &#8220;offset&#8221; in <b>\/www\/kapitalpartner_860\/public\/wp-content\/plugins\/super-rss-reader\/includes\/widget-admin.php<\/b> on line <b>60<\/b><br \/>\n<br \/>\n<b>Warning<\/b>:  Undefined array key &#8220;scroll_height&#8221; in <b>\/www\/kapitalpartner_860\/public\/wp-content\/plugins\/super-rss-reader\/includes\/widget-admin.php<\/b> on line <b>79<\/b><br \/>\n\t\t<div class=\"elementor-element elementor-element-42d472b elementor-widget elementor-widget-wp-widget-super_rss_reader\" data-id=\"42d472b\" data-element_type=\"widget\" data-widget_type=\"wp-widget-super_rss_reader.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<!-- Start - Super RSS Reader v5.2-->\r\n        <div class=\"super-rss-reader-widget\"><div class=\"srr-main\"><div class=\"srr-wrap srr-style-grey\" data-visible=\"12\" data-speed=\"5000\" data-id=\"srr-tab-239\" ><div class=\"srr-inner\"><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"26 April 2026, 7:41 pm UTC\">26 April 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/major-shareholding-notification---share-transfer-and-ownership-restructuring---related-party-transac,c4340292\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Major Shareholding Notification - share transfer and ownership restructuring \u2013 related party transaction\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, 26 April 2026 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS) announces that the company has received notification that AK 2014 Holding ApS, Krasilnikoff Holding ApS and UK Curacap ApS have merged their holding of shares in Curacap II ApS. This announcement is published in accordance with the applicable major shareholding notification rules of Spotlight Stock Market.\nBackground\n\nIt is hereby announced that a change in the shareholding structure of a technical nature has been completed following an internal restructuring between existing major shareholders.\n\nCo-<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"25 March 2026, 4:14 pm UTC\">25 March 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/resolutions-of-the-annual-general-meeting-2026-of-curasight-a-s,c4326705\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Resolutions of the Annual General Meeting 2026 of Curasight A\/S\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 25 March 2026 \u2013 today Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; \u2013 TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark\nToday, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda:\n\n 1. The Board of Directors\u2019 report on the Company\u2019s activities in the past financial year\n\nThe general meeting took note of the Board of Directors\u2019 report on the Company\u2019s activities in 2025.\n\n 2. Presentation and approval of the annual report<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"10 March 2026, 5:26 pm UTC\">10 March 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/notice-of-annual-general-meeting-2026,c4319469\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Notice of Annual General Meeting 2026\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">March 25, 2026\n\nThe Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A\/S (\u201cCurasight\u201d or the \u201cCompany\u201d \u2013 TICKER: CURAS) on Wednesday 25 March 2026 at 10.00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.\nAgenda\n\n 1. The Board of Directors\u2019 report on the Company\u2019s activities in the preceding financial year\n\u00a0\n 2. Presentation and approval of the annual report\n\n 3. Resolution on appropriation of profit or covering of loss as recorded in the annual report\n\n 4. Election of members to the Board of<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"6 March 2026, 5:26 pm UTC\">6 March 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-reduces-convertible-debt-as-fenja-capital-converts-and-enters-into-a-block-trade,c4318114\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Curasight A\/S (\u201cCurasight\u201d or the \u201cCompany\u201d \u2013 TICKER: CURAS) issued a convertible loan note to Fenja Capital II A\/S (\u201cFenja Capital\u201d) on 29 December 2025, with a nominal amount of DKK 25 million. Fenja Capital has now exercised its right to partially convert the convertible loan, whereby a total of 429,363 new ordinary shares has been issued at a conversion price of DKK 9,975 per share, corresponding to a nominal value of approximately DKK 4.3 million. In connection with the conversion, all of the converted shares have been sold by Fenja Capital in a block transaction executed between Fenja<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"26 February 2026, 7:05 am UTC\">26 February 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/annual-report-2025,c4313252\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Annual Report 2025\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 26 February 2026 &#8211; Curasight A\/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform \u00a0across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company&#8217;s website. Below is a summary of the report.\nCurasight\u2019s CEO Ulrich Krasilnikoff comments:\n\n\u201c2025 was a transformative year for Curasight. We transitioned from platform validation to active clinical execution by dosing the first patient in our Phase<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"26 February 2026, 7:00 am UTC\">26 February 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/year-end-report-q4-2025,c4313222\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Year-end report Q4 2025\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 26 February 2026 &#8211; Curasight A\/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform \u00a0addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company&#8217;s website. Below is a summary of the report.\nCurasight\u2019s CEO Ulrich Krasilnikoff comments:\n\n\u201cQ4 2025 marked strong momentum, as we advanced the company to become a clinical-stage therapeutic company pioneering uTREAT\u00ae &#8211; our first-<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"17 February 2026, 5:59 am UTC\">17 February 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight to present at TD Cowen&#039;s 46th Annual Health Care Conference in Boston\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">COPENHAGEN, Denmark, February 17, 2026 &#8211; Curasight A\/S (TICKER:CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT\u00ae in glioblastoma, at the TD Cowen 46[th]\u00a0Annual Health Care Conference on Tuesday, March 3[rd], 2026, at 11:50 a.m. Eastern Time \/ 5:50 p.m. CET in Boston.\nA live audio webcast will be broadcast over the internet simultaneously and will be available in the investor section on<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"9 February 2026, 4:16 pm UTC\">9 February 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/major-shareholding-notification,c4304883\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Major Shareholding Notification\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, 9 February 2026 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.\nPrior to the transaction, the shareholder held 5.29% of the share capital and voting rights in the Company. Following the transaction, the shareholder holds now 4.85%, corresponding to an ownership interest below 5%.\n\nThis announcement is published in accordance with the applicable major shareholding<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"12 January 2026, 5:00 pm UTC\">12 January 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-announces-encouraging-preliminary-data-from-phase-1-trial-evaluating-first-in-class-radiop,c4291355\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT[\u00ae] in High-Grade Gliomas\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">\u00b7 Clear uptake of uTREAT\u00ae in aggressive brain cancer (glioblastoma)\n  \u00b7 Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors\n\u00a0\n\nCopenhagen, 12[th] January, 2026 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT\u00ae targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion,<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"5 January 2026, 9:30 am UTC\">5 January 2026<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-to-hold-meetings-in-san-francisco-during-j-p--morgan-healthcare-conference-week,c4288616\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, 5 January 2026 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kj\u00e6r will be in San Francisco during the 44[th]\u00a0J.P. Morgan Healthcare Conference being held January 12-15, 2026.\nDuring the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company\u2019s clinical progress, including the recent initiation of a Phase 1 trial with<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"29 December 2025, 12:18 pm UTC\">29 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-a-s-resolves-to-issue-a-convertible-loan-note,c4287118\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight A\/S resolves to issue a convertible loan note\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE \u201cIMPORTANT INFORMATION\u201d SECTION AT THE END OF THIS PRESS RELEASE.\n\nCurasight A\/S (&#8220;Curasight&#8221; or the &#8220;Company&#8221; \u2013 TICKER: CURAS) has, as previously communicated on 12 December 2025, entered into a loan agreement<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"29 December 2025, 9:31 am UTC\">29 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/resolutions-of-the-extraordinary-general-meeting-december-2025,c4287043\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Resolutions of the Extraordinary General Meeting December 2025\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, 29 December 2025 \u2013 Curasight A\/S (\u201cCurasight\u201d or the \u201cCompany\u201d \u2013 TICKER: CURAS) today held its Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark\nToday, the shareholders in Curasight passed the following resolutions at the Extraordinary General Meeting in accordance with the agenda:\n\n1. Proposals from the Board of Directors\n\n1.1 Authorisation to the Board of Directors to issue one or more convertible loan notes.\n\nThe general meeting adopted the proposal to authorise the Board of Directors to issue one or more<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"18 December 2025, 4:19 pm UTC\">18 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-announces-successful-dosing-of-first-patient-in-phase-1-trial-with-utreat--in-brain-cancer,c4284416\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT[\u00ae] in Brain Cancer\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">\u00b7 Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT\u00ae belonging to Curasight\u2019s treatment platform\n  \u00b7 No patient safety issues were reported\n  \u00b7 The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT\u00ae) and diagnostic (uTRACE\u00ae) platforms\n\nCopenhagen, 18 December 2025 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"14 December 2025, 4:34 pm UTC\">14 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/notice-of-extraordinary-general-meeting,c4281603\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Notice of Extraordinary General Meeting\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">The Board of Directors is pleased to invite shareholders of Curasight A\/S (\u201cCurasight\u201d or the \u201cCompany\u201d) to an Extraordinary General Meeting on\n\n29 December 2025 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.\nAgenda\n\n 1. Proposals from the Board of Directors\n\n 1.\n\n1.1 Authorisation to the Board of Directors to issue one or more convertible loan notes\n\n1.2 Authorisation to the chairman of the meeting\n\nComplete proposals\n\n1. Proposals from the Board of Directors\n\nThe Board of Directors makes the proposals in items 1.1 and 1.2.<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"12 December 2025, 9:37 pm UTC\">12 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-a-s-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-16-4-millio,c4281385\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight A\/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE \u201cIMPORTANT INFORMATION\u201d SECTION AT THE END OF THIS PRESS RELEASE.\n\nCurasight A\/S (&#8220;Curasight&#8221; or the &#8220;Company&#8221; \u2013 TICKER: CURAS) has, in accordance with the intention announced by the Company through a press release,<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"12 December 2025, 5:38 pm UTC\">12 December 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-a-s-announces-its-intention-to-carry-out-a-directed-issue-of-shares-and-enter-into-a-new-l,c4281356\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight A\/S announces its intention to carry out a directed issue of shares and enter into a new loan facility\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE \u201cIMPORTANT INFORMATION\u201d SECTION AT THE END OF THIS PRESS RELEASE.\n\nCurasight A\/S (&#8220;Curasight&#8221; or the &#8220;Company&#8221; \u2013 TICKER: CURAS) hereby announces its intention to carry out a directed issue of shares of a minimum of<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"28 November 2025, 10:09 am UTC\">28 November 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-to-present-at-hc-andersen-capital,c4274220\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight to present at HC Andersen Capital\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 28 November 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; &#8211; TICKER: CURAS) hereby\u00a0announces that CEO Ulrich Krasilnikoff and CMO professor Andreas Kj\u00e6r will present the Q3 2025 Interim report and the company\u2019s latest progress and strategy at HC Andersen Capital.\nThe presentations will include an update on the business progress made by the company during the first three quarters of 2025 and look ahead at the expected coming news flow.\n\nManagement will give an overall update on the company\u2019s pipeline based on the proprietary uPAR theranostics platform and focused on<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"27 November 2025, 6:00 am UTC\">27 November 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/interim-report-q3-2025,c4273312\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Interim report Q3 2025\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 27 November 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or &#8220;the Company&#8221; &#8211; TICKER: CURAS) hereby publishes the interim report Q3 2025. The interim report is available as an attached file to this release and on the Company&#8217;s website. Below is a summary of the report.\nCurasight\u2019s CEO Ulrich Krasilnikoff comments:\n\n\u201cDuring the third quarter of 2025 and period after, Curasight continued to make significant clinical and strategic progress as we advance our mission to improve outcomes for patients with serious cancers through precision diagnostics and targeted radionuclide therapy.<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"26 November 2025, 6:11 am UTC\">26 November 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-s-utreat--phase-1-trial-in-brain-cancer-now-open-for-patient-enrollment,c4272662\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight\u2019s\u00a0uTREAT\u00ae Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">\u00b7 Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT\u00ae\n  \u00b7 Site given green light by European Medicines Agency (EMA) and is now open for patient enrollment \u2013 first patient dosing expected Q4 2025\n  \u00b7 Both arms of Curasight\u2019s theranostic approach investigating better treatment (uTREAT\u00ae) and diagnosis (uTRACE\u00ae) of certain cancers are now in clinical development\n\nCopenhagen, 26 November 2025 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced its phase 1 trial<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"13 November 2025, 7:23 am UTC\">13 November 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-to-present-at-dansk-aktionaerforening-investordagen,c4266479\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight to present at Dansk Aktion\u00e6rforening InvestorDagen\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 13 November 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; &#8211; TICKER: CURAS) hereby\u00a0announces that CEO Ulrich Krasilnikoff will present the company\u2019s latest progress and strategy at Dansk Aktion\u00e6rforening InvestorDagen in Copenhagen on Monday, 17th November 2025.\nManagement will provide an overall update on the company\u2019s pipeline based on Curasight\u2019s \u00a0proprietary uPAR theranostics platform which is aimed at improving diagnosis and treatment of certain types of cancers including prostate and brain cancer. The presentation will also highlight key near-term milestones<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"29 October 2025, 7:10 am UTC\">29 October 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-advances-phase-2-utrace-prostate-cancer-trial-with-all-european-clinical-sites-in-part-2-n,c4258162\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">\u00b7 Part 1 of the trial is completed \u00a0\n  \u00b7 Part 2 recruitment well underway; completion expected in the first half of 2026\n  \u00b7 The Phase 2 study in prostate cancer is part of the agreement between Curium Inc. and Curasight signed in May 2023\n\nCopenhagen, Denmark, 29 October 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; &#8211; TICKER: CURAS) announces today strong momentum in part 2 of the Phase 2 Study investigating the company\u2019s diagnostic platform uTRACE\u00ae in prostate cancer. All nine sites across Germany, Sweden and Denmark are now fully activated and recruiting patients following the<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"1 October 2025, 5:00 am UTC\">1 October 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/curasight-announces-broadening-and-extension-of-patent-protection-for-utrace-,c4243563\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Curasight announces broadening and extension of patent protection for uTRACE\u00ae\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">\u00b7 Issuance of new patent related to uTRACE\u00ae will broaden protection\n  \u00b7 Patent coverage has been extended by 751 days and now expires 2035\n  \u00b7 Strengthened patent protection significantly enhances the potential financial value of uTRACE\u00ae\n\nCopenhagen, Denmark, 01 October 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; &#8211; TICKER: CURAS) announces today the issuance of US patent 12,409,240 B2 which expands the protection of the company\u2019s uPAR diagnostic platform, uTRACE. The patent term has also been extended by 751 days (more than 2 years) so that it now expires in 2035. \u00a0This<\/div><\/div><\/div><div class=\"srr-item \"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"3 September 2025, 7:51 pm UTC\">3 September 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/transaction-with-shares-in-curasight-a-s-made-by-managerial-employee,c4229438\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Transaction with shares in Curasight A\/S made by managerial employee\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 3 September 2025 &#8211; Curasight A\/S (&#8220;Curasight&#8221; or the \u201cCompany&#8221; &#8211; TICKER: CURAS) hereby\u00a0announces in accordance with Article 19 of Regulation No. 596\/2014 on Market Abuse and Implementing Regulation 2016\/523, this document discloses the data of the transaction made in Curasight made by managerial employee.\u00a0\n\nThe Company\u2019s managerial employee have given Curasight power of attorney on her behalf to publish sales of Curasight shares as managerial employee conducted 1 September 2025.\nThe transaction comprise the following managerial employee;\n\nName    Position<\/div><\/div><\/div><div class=\"srr-item srr-stripe\"><div class=\"srr-item-in srr-clearfix\"><div class=\"srr-meta\"><time class=\"srr-date\" title=\"28 August 2025, 5:00 am UTC\">28 August 2025<\/time><\/div><a href=\"https:\/\/news.cision.com\/curasight\/r\/half-year-report-q2-2025,c4225556\" class=\"srr-thumb srr-thumb-align_left\" style=\"width:100px;height:100px;\"  target=\"_blank\" rel=\"nofollow noopener noreferrer\"><img decoding=\"async\" src=\"https:\/\/mb.cision.com\/Public\/19744\/logo\/92580e56486c5f4b_org.jpg\" alt=\"Half-year report Q2 2025\" align=\"left\" \/><\/a><div class=\"srr-summary srr-clearfix\">Copenhagen, Denmark, 28 August 2025 &#8211; Curasight A\/S (\u201cCurasight\u201d or \u201cthe Company\u201d \u2013 TICKER: CURAS) hereby publishes the half-year report 2025. The interim report is available as an attached file to this release and on the Company\u2019s website. Below is a summary of the report.\nCurasight\u2019s CEO Ulrich Krasilnikoff comments:\n\n\u201cIn the second quarter of 2025, we were pleased to complete a capital injection of around DKK 65 million from a mix of fresh capital and new and renegotiated loans. This funding allows us to build on our theranostic approach of using radiopharmacueticals to develop more<\/div><\/div><\/div><\/div><\/div><\/div><\/div><!-- End - Super RSS Reader -->\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-791cce2 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"791cce2\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-2472a173\" data-id=\"2472a173\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1d7df4aa elementor-widget elementor-widget-spacer\" data-id=\"1d7df4aa\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-39c78992 elementor-section-stretched elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"39c78992\" data-element_type=\"section\" data-settings=\"{&quot;stretch_section&quot;:&quot;section-stretched&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-3058ffb7\" data-id=\"3058ffb7\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4410e287 elementor-widget elementor-widget-text-editor\" data-id=\"4410e287\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><a href=\"https:\/\/kapitalpartner.dk\/en\/\">Front page<\/a> &gt; <a href=\"https:\/\/kapitalpartner.dk\/en\/investeringscases\/\">Investment cases<\/a> &gt; Curasight<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-34fff51c\" data-id=\"34fff51c\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap\">\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7fdcfa9e elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7fdcfa9e\" data-element_type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-1d4d8ab5\" data-id=\"1d4d8ab5\" data-element_type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-288d4108 elementor-widget elementor-widget-spacer\" data-id=\"288d4108\" data-element_type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Front page &gt; Investment cases &gt; Curasight About Curasight Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers. The company has developed a radiopharmaceutical platform that can be used both [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":14484,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11410","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Curasight | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/curasight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curasight | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Front page &gt; Investment cases &gt; Curasight About Curasight Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers. The company has developed a radiopharmaceutical platform that can be used both [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/curasight\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-17T13:18:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"850\" \/>\n\t<meta property=\"og:image:height\" content=\"569\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/\",\"name\":\"Curasight | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg\",\"datePublished\":\"2022-01-05T13:38:26+00:00\",\"dateModified\":\"2025-01-17T13:18:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/curasight\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg\",\"width\":850,\"height\":569},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/curasight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curasight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curasight | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/curasight\/","og_locale":"en_US","og_type":"article","og_title":"Curasight | Kapital Partner A\/S","og_description":"Front page &gt; Investment cases &gt; Curasight About Curasight Curasight is a clinical phase II company with a technology built around the uPAR receptor, which is a biomarker expressed in most solid cancers. Curasight operates in the diagnosis and treatment of various cancers. The company has developed a radiopharmaceutical platform that can be used both [&hellip;]","og_url":"https:\/\/kapitalpartner.dk\/en\/curasight\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_modified_time":"2025-01-17T13:18:20+00:00","og_image":[{"width":850,"height":569,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@KapitalPartner","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/","url":"https:\/\/kapitalpartner.dk\/en\/curasight\/","name":"Curasight | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg","datePublished":"2022-01-05T13:38:26+00:00","dateModified":"2025-01-17T13:18:20+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/curasight\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/02\/Curasight-Ny-W-logo-1.jpg","width":850,"height":569},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/curasight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Curasight"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/pages\/11410"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=11410"}],"version-history":[{"count":15,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/pages\/11410\/revisions"}],"predecessor-version":[{"id":45189,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/pages\/11410\/revisions\/45189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/14484"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=11410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}